Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

Autor: Jang S; Elevar Therapeutics, Fort Lee, NJ, USA. sjang@elevartherapeutics.com., Strickland B; Elevar Therapeutics, Fort Lee, NJ, USA., Finis L; Elevar Therapeutics, Fort Lee, NJ, USA., Kooijman JJ; Oncolines B.V., Oss, The Netherlands., Melis JJTM; Oncolines B.V., Oss, The Netherlands., Zaman GJR; Oncolines B.V., Oss, The Netherlands., Van Tornout J; Elevar Therapeutics, Fort Lee, NJ, USA.
Jazyk: angličtina
Zdroj: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Jun; Vol. 91 (6), pp. 491-499. Date of Electronic Publication: 2023 May 06.
DOI: 10.1007/s00280-023-04534-7
Abstrakt: Vascular endothelial growth factor receptor 2 (VEGFR2), a key regulator of tumor angiogenesis, is highly expressed across numerous tumor types and has been an attractive target for anti-cancer therapy. However, clinical application of available VEGFR2 inhibitors has been challenged by limited efficacy and a wide range of side effects, potentially due to inadequate selectivity for VEGFR2. Thus, development of potent VEGFR2 inhibitors with improved selectivity is needed. Rivoceranib is an orally administered tyrosine kinase inhibitor that potently and selectively targets VEGFR2. A comparative understanding of the potency and selectivity of rivoceranib and approved inhibitors of VEGFR2 is valuable to inform rationale for therapy selection in the clinic. Here, we performed biochemical analyses of the kinase activity of VEGFR2 and of a panel of 270 kinases to compare rivoceranib to 10 FDA-approved kinase inhibitors ("reference inhibitors") with known activity against VEGFR2. Rivoceranib demonstrated potency within the range of the reference inhibitors, with a VEGFR2 kinase inhibition IC 50 value of 16 nM. However, analysis of residual kinase activity of the panel of 270 kinases showed that rivoceranib displayed greater selectivity for VEGFR2 compared with the reference inhibitors. Differences in selectivity among compounds within the observed range of potency of VEGFR2 kinase inhibition are clinically relevant, as toxicities associated with available VEGFR2 inhibitors are thought to be partly due to their effects against kinases other than VEGFR2. Together, this comparative biochemical analysis highlights the potential for rivoceranib to address clinical limitations associated with off-target effects of currently available VEGFR2 inhibitors.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: